Laurus Labs Limited has released its consolidated unaudited financial results for the quarter ended December 31, 2024. The results highlight steady performance across revenue and profitability metrics.
Key Financial Highlights (Q3 FY25 vs Q3 FY24):
- Revenue from Operations: ₹1,415.05 crore, up 18.4% from ₹1,194.92 crore in Q3 FY24.
- Total Income: ₹1,424.47 crore, an increase of 18.9% YoY from ₹1,197.35 crore.
- Net Profit: ₹92.89 crore, a growth of 297% YoY compared to ₹23.34 crore in the same quarter last year.
- EBITDA: ₹218.26 crore, reflecting robust operational efficiency.
Nine-Month Performance:
- Revenue from Operations: ₹3,833.66 crore, up 6.5% YoY from ₹3,601.16 crore.
- Net Profit: ₹125.57 crore, a significant increase from ₹62.27 crore, reflecting improved profitability.
Operational Highlights:
- The company achieved higher revenue from its active pharmaceutical ingredient (API) and formulation businesses.
- Cost of materials consumed was ₹653 crore in Q3 FY25, slightly down from ₹634.12 crore in Q3 FY24, indicating better cost efficiency.
- Total expenses rose to ₹1,293.79 crore in Q3 FY25 compared to ₹1,162.73 crore in Q3 FY24, mainly due to higher employee benefit and depreciation expenses.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
TOPICS:
Laurus Labs